May 24th, 2022 (Earnings Report)Dear Reader,Our scanners just identified several healthtech stocks that are expected to release earnings starting November 21st, 2022.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Enanta Pharmaceuticals
Symbol: ENTA
Recent Price: $45.87
Average Analyst Price Target: $90.20 (96.64%)
Market Cap: $952.51M
Last Year's EPS: -$1.22
Consensus EPS Forecast: -$1.31
Expected Earnings Date: Nov 20 2022
Recent Analyst Action: Brian Skorney, analyst at Robert W. Baird, reiterates coverage on Enanta Pharmaceuticals (ENTA) in the Healthcare sector with a Buy rating and a price target of $ 90 (1 week ago).
TipRanks.com also reports that Enanta Pharmaceuticals currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $90.20 . The target pricing ranges from a high forecast of $112.00 down to a low forecast of $65.00. Enanta Pharmaceuticals (ENTA)’s last closing price was $45.87 which would put the average price target at 96.64% upside.Here are 3rd party ratings for ENTA:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 32% (81 out of 251)
--------------------------------------------------------------------------
Enlivex Therapeutics
Symbol: ENLV
Recent Price: $4.8
Average Analyst Price Target: $15.00 (212.50%)
Market Cap: $87.87M
Last Year's EPS: -$0.21
Consensus EPS Forecast: -$0.29
Expected Earnings Date: Nov 20 2022
Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on Enlivex Therapeutics (ENLV) in the Healthcare sector with a Buy rating and a price target of $ 15 (1 month ago).
TipRanks.com also reports that Enlivex Therapeutics currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.00 . The target pricing ranges from a high forecast of $15.00 down to a low forecast of $15.00. Enlivex Therapeutics (ENLV)’s last closing price was $4.8 which would put the average price target at 212.50% upside.Here are 3rd party ratings for ENLV:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 32% (81 out of 251)
--------------------------------------------------------------------------
Frequency Therapeutics
Symbol: FREQ
Recent Price: $1.88
Average Analyst Price Target: $10.00 (431.91%)
Market Cap: $73.70M
Last Year's EPS: -$0.73
Consensus EPS Forecast: -$0.57
Expected Earnings Date: Nov 20 2022
Recent Analyst Action: Jack Allen, analyst at Robert W. Baird, reiterates coverage on Frequency Therapeutics (FREQ) in the Healthcare sector with a Buy rating and a price target of $ 10 (1 week ago).
TipRanks.com also reports that Frequency Therapeutics currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.00 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $10.00. Frequency Therapeutics (FREQ)’s last closing price was $1.88 which would put the average price target at 431.91% upside.Here are 3rd party ratings for FREQ:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 24% (59 out of 251)
--------------------------------------------------------------------------
Ibio
Symbol: IBIO
Recent Price: $1.71
Average Analyst Price Target: $3.63 (112.28%)
Market Cap: $15.67M
Last Year's EPS: -$1
Consensus EPS Forecast: -$25.38
Expected Earnings Date: Nov 20 2022
Recent Analyst Action: Roy Buchanan, analyst at JMP Securities, reiterates coverage on Ibio (IBIO) in the Healthcare sector with a Buy rating and a price target of $ 3 (22 hours ago).
TipRanks.com also reports that Ibio currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $3.63 . The target pricing ranges from a high forecast of $4.25 down to a low forecast of $3.00. Ibio (IBIO)’s last closing price was $1.71 which would put the average price target at 112.28% upside.Here are 3rd party ratings for IBIO:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 24% (59 out of 251)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
